KemPharm, Inc. (KMPH) Reaches $5.70 After 4.00% Down Move; First Foundation Advisors Trimmed Lam Research (LRCX) Position By $1.20 Million

February 15, 2018 - By Jonathan Benavides

The stock of KemPharm, Inc. (NASDAQ:KMPH) is a huge mover today! The stock decreased 6.56% or $0.4 during the last trading session, reaching $5.7. About 76,552 shares traded or 8.45% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has declined 32.16% since February 15, 2017 and is downtrending. It has underperformed by 48.86% the S&P500.The move comes after 7 months negative chart setup for the $83.55 million company. It was reported on Feb, 15 by We have $5.47 PT which if reached, will make NASDAQ:KMPH worth $3.34 million less.

First Foundation Advisors decreased Lam Research Corp (LRCX) stake by 81.03% reported in 2017Q3 SEC filing. First Foundation Advisors sold 6,478 shares as Lam Research Corp (LRCX)’s stock rose 32.64%. The First Foundation Advisors holds 1,517 shares with $281,000 value, down from 7,995 last quarter. Lam Research Corp now has $29.94 billion valuation. The stock increased 0.39% or $0.72 during the last trading session, reaching $183.73. About 2.72 million shares traded. Lam Research Corporation (NASDAQ:LRCX) has risen 107.86% since February 15, 2017 and is uptrending. It has outperformed by 91.16% the S&P500.

Among 25 analysts covering Lam Research Corporation (NASDAQ:LRCX), 24 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Lam Research Corporation had 79 analyst reports since September 17, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, June 13 by UBS. The stock of Lam Research Corporation (NASDAQ:LRCX) has “Buy” rating given on Thursday, January 25 by Needham. As per Thursday, January 26, the company rating was maintained by Cowen & Co. The rating was maintained by Needham on Friday, October 9 with “Buy”. The stock has “Overweight” rating by Pacific Crest on Thursday, March 16. The firm has “Buy” rating by RBC Capital Markets given on Thursday, July 27. The firm has “Buy” rating given on Thursday, October 20 by B. Riley & Co. On Wednesday, October 18 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The firm has “Outperform” rating given on Friday, January 13 by RBC Capital Markets. RBC Capital Markets maintained Lam Research Corporation (NASDAQ:LRCX) rating on Thursday, January 25. RBC Capital Markets has “Buy” rating and $245.0 target.

Investors sentiment increased to 1.02 in Q3 2017. Its up 0.04, from 0.98 in 2017Q2. It increased, as 51 investors sold LRCX shares while 238 reduced holdings. 87 funds opened positions while 207 raised stakes. 146.35 million shares or 1.92% less from 149.22 million shares in 2017Q2 were reported. Korea Invest has invested 0.4% of its portfolio in Lam Research Corporation (NASDAQ:LRCX). Cwm Lc stated it has 388 shares or 0% of all its holdings. Proshare Advsr Limited Liability holds 0.16% or 92,419 shares. State Treasurer State Of Michigan invested in 0.07% or 49,260 shares. Oppenheimer Asset Mngmt reported 741 shares. Gemmer Asset Mgmt holds 0.01% or 171 shares. C M Bidwell And Associates Ltd accumulated 1,080 shares. Marvin Palmer Assocs Inc holds 5.47% or 24,073 shares. Daiwa Sb Invests Limited holds 0% of its portfolio in Lam Research Corporation (NASDAQ:LRCX) for 90 shares. Strs Ohio invested in 57,553 shares. Shell Asset Mngmt Co holds 0.03% of its portfolio in Lam Research Corporation (NASDAQ:LRCX) for 24,769 shares. Wespac Ltd stated it has 4,363 shares or 0.53% of all its holdings. Old Mutual Customised Solutions (Proprietary) invested in 5,011 shares. Foundry Ptnrs Limited Company invested in 84,050 shares. Davenport And Company Limited Liability Company holds 0% of its portfolio in Lam Research Corporation (NASDAQ:LRCX) for 1,381 shares.

First Foundation Advisors increased Twenty First Centy Fox Cl A (NASDAQ:FOXA) stake by 21,112 shares to 774,769 valued at $20.44 million in 2017Q3. It also upped Molson Coors Brewing Co (NYSE:TAP) stake by 6,635 shares and now owns 20,302 shares. Facebook Inc (NASDAQ:FB) was raised too.

Since September 11, 2017, it had 0 buys, and 11 selling transactions for $12.77 million activity. $1.49M worth of Lam Research Corporation (NASDAQ:LRCX) was sold by ARCHER TIMOTHY. 25,453 shares were sold by Varadarajan Seshasayee, worth $5.47 million. NEWBERRY STEPHEN G also sold $131,250 worth of Lam Research Corporation (NASDAQ:LRCX) shares.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $83.55 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: